Publications by authors named "David A Claremon"

Claim this Profile
D
Discovery of Potent Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1 Using a Novel Growth-Based Protocol of Screening and Optimization in CONTOUR.
Zhijie Liu, Suresh B Singh, Yajun Zheng, Peter Lindblom, Colin Tice, David A Claremon

J Chem Inf Model· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of BI 135585, an in vivo efficacious oxazinanone-based 11β hydroxysteroid dehydrogenase type 1 inhibitor.
Linghang Zhuang, Colin M Tice, Zhenrong Xu, Wei Zhao, Salvacion Cacatian, David A Claremon

Bioorg Med Chem· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of sub-chronic selective 11β-hydroxysteroid dehydrogenase 1 inhibition on the hypothalamic-pituitary-adrenal axis in female cynomolgus monkeys.
Bradford S Hamilton, Corinna Schoelch, Annette Schuler-Metz, Paula Krosky, Deepak S Lala, David A Claremon

Eur J Pharmacol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brain penetrant liver X receptor (LXR) modulators based on a 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole core.
Colin M Tice, Paul B Noto, Kristi Yi Fan, Wei Zhao, Stephen D Lotesta, David A Claremon

Bioorg Med Chem Lett· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Novel, Orally Efficacious Liver X Receptor (LXR) β Agonist.
Yajun Zheng, Linghang Zhuang, Kristi Yi Fan, Colin M Tice, Wei Zhao, David A Claremon

J Med Chem· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacological characterization of the selective 11β-hydroxysteroid dehydrogenase 1 inhibitor, BI 135585, a clinical candidate for the treatment of type 2 diabetes.
Bradford S Hamilton, Frank Himmelsbach, Herbert Nar, Annette Schuler-Metz, Paula Krosky, David A Claremon

Eur J Pharmacol· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An electronic environment and contact direction sensitive scoring function for predicting affinities of protein-ligand complexes in Contour(®).
Peter R Lindblom, Guosheng Wu, Zhijie Liu, Kam-Chuen Jim, John J Baldwin, David A Claremon

J Mol Graph Model· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-based design technology contour and its application to the design of renin inhibitors.
Alexey Ishchenko, Zhijie Liu, Peter Lindblom, Guosheng Wu, Kam-Chuen Jim, David A Claremon

J Chem Inf Model· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of VTP-27999, an Alkyl Amine Renin Inhibitor with Potential for Clinical Utility.
Lanqi Jia, Robert D Simpson, Jing Yuan, Zhenrong Xu, Wei Zhao, David A Claremon

ACS Med Chem Lett· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-based design and synthesis of 1,3-oxazinan-2-one inhibitors of 11β-hydroxysteroid dehydrogenase type 1.
Zhenrong Xu, Colin M Tice, Wei Zhao, Salvacion Cacatian, Yuan-Jie Ye, David A Claremon

J Med Chem· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biphenyl/diphenyl ether renin inhibitors: filling the S1 pocket of renin via the S3 pocket.
Jing Yuan, Robert D Simpson, Wei Zhao, Colin M Tice, Zhenrong Xu, David A Claremon

Bioorg Med Chem Lett· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and optimization of adamantyl carbamate inhibitors of 11β-HSD1.
Colin M Tice, Wei Zhao, Paula M Krosky, Barbara A Kruk, Jennifer Berbaum, David A Claremon

Bioorg Med Chem Lett· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spirocyclic ureas: orally bioavailable 11 beta-HSD1 inhibitors identified by computer-aided drug design.
Colin M Tice, Wei Zhao, Zhenrong Xu, Salvacion T Cacatian, Robert D Simpson, David A Claremon

Bioorg Med Chem Lett· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of orally bioavailable alkyl amine renin inhibitors.
Zhenrong Xu, Salvacion Cacatian, Jing Yuan, Robert D Simpson, Lanqi Jia, David A Claremon

Bioorg Med Chem Lett· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and evaluation of novel tricyclic benzo[4.5]cyclohepta[1.2]pyridine derivatives as NMDA/NR2B antagonists.
Charles J McIntyre, John A McCauley, Bohumil Bednar, Rodney A Bednar, John W Butcher, David A Claremon

Bioorg Med Chem Lett· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and optimization of renin inhibitors: Orally bioavailable alkyl amines.
Colin M Tice, Zhenrong Xu, Jing Yuan, Robert D Simpson, Salvacion T Cacatian, David A Claremon

Bioorg Med Chem Lett· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyclic benzamidines as orally efficacious NR2B-selective NMDA receptor antagonists.
Kevin T Nguyen, Christopher F Claiborne, John A McCauley, Brian E Libby, David A Claremon

Bioorg Med Chem Lett· July 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.
Nigel J Liverton, Rodney A Bednar, Bohumil Bednar, John W Butcher, Christopher F Claiborne, David A Claremon

J Med Chem· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NR2B-selective N-methyl-D-aspartate antagonists: synthesis and evaluation of 5-substituted benzimidazoles.
John A McCauley, Cory R Theberge, Joseph J Romano, Susan B Billings, Kenneth D Anderson, David A Claremon

J Med Chem· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo canine cardiac electrophysiologic profile of 1,4-benzodiazepine IKs blockers.
Gary L Stump, Garry R Smith, Andrew J Tebben, Hossain Jahansouz, Joseph J Salata, David A Claremon

J Cardiovasc Pharmacol· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel 5-cyclopropyl-1,4-benzodiazepin-2-ones as potent and selective I(Ks)-blocking class III antiarrhythmic agents.
John W Butcher, Nigel J Liverton, David A Claremon, Roger M Freidinger, Nancy K Jurkiewicz

Bioorg Med Chem Lett· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Orally efficacious NR2B-selective NMDA receptor antagonists.
Christopher F Claiborne, John A McCauley, Brian E Libby, Neil R Curtis, Helen J Diggle, David A Claremon

Bioorg Med Chem Lett· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiarrhythmic efficacy of combined I(Ks) and beta-adrenergic receptor blockade.
Joseph J Lynch, Joseph J Salata, Audrey A Wallace, Gary L Stump, David B Gilberto, David A Claremon

J Pharmacol Exp Ther· July 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyridazine based inhibitors of p38 MAPK.
Charles J McIntyre, Gerald S Ponticello, Nigel J Liverton, Stephen J O'Keefe, Edward A O'Neill, David A Claremon

Bioorg Med Chem Lett· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis